PTX3: A Promising Drug Target and Biomarker for Tumor Necrosis Factor-Inducible Gene 14 Protein

Target Name: PTX3

NCBI ID: G5806

PTX3

PTX3: A Promising Drug Target and Biomarker for Tumor Necrosis Factor-Inducible Gene 14 Protein

Tumor necrosis factor-inducible gene 14 (TNFI-14) is a non-coding RNA molecule that plays a crucial role in cell signaling, particularly in the regulation of cell growth and apoptosis. It is a key regulator of the TGF-β signaling pathway, which is a well-established mechanism for the development and maintenance of cancer. Therefore, targeting the regulation of TNFI-14 is a promising strategy for the development of anti-cancer drugs.

PTX3, a tumor necrosis factor-inducible gene 14 (TNFI-14) gene, is a promising drug target and biomarker for cancer. It is a cytoplasmic protein that is expressed in various tissues and cells, including the brain, spleen, heart, and liver. PTX3 has been shown to play a critical role in the regulation of cell growth, apoptosis, and inflammation.

Expression of PTX3 and its association with cancer

The expression of PTX3 has been shown to be significantly increased in various types of cancer, including breast, lung, and colorectal cancer. It is also overexpressed in various types of cancer-related tissues, including cancer cells, stromal cells, and pericytes.

In addition to its increased expression, PTX3 has also been shown to play a critical role in the regulation of cell apoptosis. Studies have shown that PTX3 can induce cell apoptosis in various types of cancer cells, including breast, lung, and colorectal cancer cells. This is thought to occur through the regulation of the BCL-2 gene, which is a critical regulator of cell apoptosis.

Furthermore, PTX3 has also been shown to be involved in the regulation of cell proliferation. Studies have shown that PTX3 can inhibit the growth of various types of cancer cells in a dose-dependent manner, including breast, lung, and colorectal cancer cells.

Drug targeting of PTX3

The drug targeting of PTX3 has the potential to be an effective strategy for the development of anti-cancer drugs. One of the main strategies for drug targeting of PTX3 is the inhibition of its expression. This can be achieved through various methods, including small molecule inhibitors, RNA interference, and protein kinase inhibitors.

One of the most promising small molecule inhibitors of PTX3 is the drugletectin. Letectin is a natural compound that has been shown to have a negative impact on the expression of various proteins, including PTX3. Studies have shown that letectin can inhibit the expression of PTX3 in various types of cancer cells, including breast, lung, and colorectal cancer cells.

Another promising small molecule inhibitor of PTX3 is the drug ganetumab ravtansine (GAR). GAR is an inhibitor of the protein tyrosine kinase AXL, which is a critical regulator of PTX3 expression. Studies have shown that GAR can inhibit the expression of PTX3 in various types of cancer cells, including breast, lung, and colorectal cancer cells.

In addition to small molecules, RNA interference (RNAi) technology can also be used to target PTX3. RNAi is a technique that involves the introduction of small interfering RNA (siRNA) into cells to inhibit the expression of specific genes.

Targeting PTX3 through RNAi

RNAi-based approaches have been shown to be a promising strategy for drug targeting of PTX3. One of the main advantages of RNAi is its ability to selectively target the expression of specific genes, including gene expression that is dependent on the expression of a particular protein, such as PTX3.

Studies have shown that

Protein Name: Pentraxin 3

Functions: Plays a role in the regulation of innate resistance to pathogens, inflammatory reactions, possibly clearance of self-components and female fertility

The "PTX3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTX3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets